Skip to main content
. 2015 May;36(5):877–885. doi: 10.3174/ajnr.A4218

Fig 7.

Fig 7.

Recurrent tumor. Five months later after RT with concomitant and adjuvant temozolomide, this patient with glioblastoma developed a new heterogeneously enhancing mass lesion in the left occipital lobe on a contrast T1-weighted image (A) with heterogeneously increased signal on DWI (B) and decreased ADC (C). ADCLesion = 0.00123 mm2/s. rCBV map (D) shows hyperperfusion. rCBVLesion = 2.78. Repeat surgery confirmed recurrent tumor.